Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead th...
New York, New York--(Newsfile Corp. - March 24, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Alector, Inc. (NASDAQ: ALEC) breached their fiduciary duties to shareholders. The investigation concerns potential...
The following slide deck was published by Alector, Inc. in conjunction with this event. For further details see: Alector (ALEC) Presents Twelve Month Results
Treatment with AL001 (latozinemab) demonstrated target engagement and resulted in increases in progranulin levels in all patients FTD-C9orf72 patients treated with latozinemab demonstrated a trend toward a delay in disease progression relative to the ALLFTD matched control...
SOUTH SAN FRANCISCO, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will present at the following upcoming investor conferences: Barclays Global Healthc...
The shares of the clinical-stage biotech, Alector (ALEC -21.1%) have reached a 15-month low after Stifel downgraded it to Hold from Buy with cautious remarks on the company’s dementia candidate AL001. The price target lowered to $18 from $32 per share implies a premium of ~21% to the l...
Gainers: Voyager Therapeutics (NASDAQ:VYGR) +22%. 908 Devices (NASDAQ:MASS) +16%. Viemed Healthcare (NASDAQ:VMD) +10%. Cara Therapeutics (NASDAQ:CARA) +9%. Neuronetics (NASDAQ:STIM) +9%. Losers: Alector (NASDAQ:ALEC) -19%. Can-Fite BioPharma (NYSE:CANF)...
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced an oral presentation at the upcoming 2022 International Conference on Alzheimer’s and Parkinsonȁ...
SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced management will participate in a panel discussion at the ...
Alector press release (NASDAQ:ALEC): Q4 GAAP EPS of -$0.68 misses by $0.75. Revenue of $14M (+188.7% Y/Y) misses by $69.82M. For further details see: Alector GAAP EPS of -$0.68 misses by $0.75, revenue of $14M misses by $69.82M
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...